Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Nafoxidine

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Nafoxidine
Clinical data
Other namesU-11,000A; NSC-70735
Routes of
administration
By mouth
ATC code
  • None
Identifiers
  • 1-[2-[4-(6-Methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine
CAS Number
PubChemCID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.222.756Edit this at Wikidata
Chemical and physical data
FormulaC29H31NO2
Molar mass425.572 g·mol−1
3D model (JSmol)
  • COC1=CC2=C(C=C1)C(=C(CC2)C3=CC=CC=C3)C4=CC=C(C=C4)OCCN5CCCC5
  • InChI=1S/C29H31NO2/c1-31-26-14-16-28-24(21-26)11-15-27(22-7-3-2-4-8-22)29(28)23-9-12-25(13-10-23)32-20-19-30-17-5-6-18-30/h2-4,7-10,12-14,16,21H,5-6,11,15,17-20H2,1H3
  • Key:JEYWNNAZDLFBFF-UHFFFAOYSA-N

Nafoxidine (INNTooltip International Nonproprietary Name; developmental code namesU-11,000A) ornafoxidine hydrochloride (USANTooltip United States Adopted Name) is anonsteroidalselective estrogen receptor modulator (SERM) orpartialantiestrogen of thetriphenylethylene group that was developed for the treatment ofadvancedbreast cancer byUpjohn in the 1970s but was never marketed.[1][2][3] It was developed at around the same time astamoxifen andclomifene, which are also triphenylethylene derivatives.[2] The drug was originally synthesized by the fertility control program at Upjohn as apostcoital contraceptive, but was subsequently repurposed for the treatment of breast cancer.[4] Nafoxidine was assessed in clinical trials in the treatment of breast cancer and was found to be effective.[5][6] However, it producedside effects includingichthyosis, partialhair loss, andphototoxicity of the skin in almost all patients,[5] and this resulted in the discontinuation of its development.[4][7]

Nafoxidine is a long-actingestrogen receptorligand, with anuclear retention in the range of 24 to 48 hours or more.[8]

Comparison of early clinical experience with antiestrogens for advanced breast cancer
AntiestrogenDosageYear(s)Response rateAdverse effects
Ethamoxytriphetol500–4,500 mg/day196025%Acute psychotic episodes
Clomifene100–300 mg/day1964–197434%Risks ofcataracts
Nafoxidine180–240 mg/day197631%Cataracts,ichthyosis,photophobia
Tamoxifen20–40 mg/day1971–197331%Transientthrombocytopeniaa
Footnotes:a = "The particular advantage of this drug is the low incidence of troublesome side effects (25)." "Side effects were usually trivial (26)."Sources:[9][10]

References

[edit]
  1. ^Elks J (14 November 2014).The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 848–.ISBN 978-1-4757-2085-3.
  2. ^abCraig JV, Furr BJ (5 February 2010).Hormone Therapy in Breast and Prostate Cancer. Springer Science & Business Media. pp. 95–96.ISBN 978-1-59259-152-7.
  3. ^Weber GF (22 July 2015).Molecular Therapies of Cancer. Springer. pp. 361–.ISBN 978-3-319-13278-5.
  4. ^abMcDaniel RE, Maximov PY, Jordan VC (2013)."Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story".Vitamins and Hormones.93:1–49.doi:10.1016/B978-0-12-416673-8.00007-1.PMID 23810002.
  5. ^abCoelingh Bennink HJ, Verhoeven C, Dutman AE, Thijssen J (January 2017)."The use of high-dose estrogens for the treatment of breast cancer".Maturitas.95:11–23.doi:10.1016/j.maturitas.2016.10.010.PMID 27889048.
  6. ^Steinbaum FL, De Jager RL, Krakoff IH (1978). "Clinical trial of nafoxidine in advanced breast cancer".Medical and Pediatric Oncology.4 (2):123–126.doi:10.1002/mpo.2950040207.PMID 661750.
  7. ^Lupulescu A (24 October 1990).Hormones and Vitamins in Cancer Treatment. CRC Press. pp. 95–.ISBN 978-0-8493-5973-6.
  8. ^Hammond CB, Maxson WS (January 1982). "Current status of estrogen therapy for the menopause".Fertility and Sterility.37 (1):5–25.doi:10.1016/S0015-0282(16)45970-4.PMID 6277697.
  9. ^Jensen EV, Jordan VC (June 2003)."The estrogen receptor: a model for molecular medicine".Clin. Cancer Res.9 (6):1980–9.PMID 12796359.
  10. ^Howell A, Jordan VC (2013). "Adjuvant Antihormone Therapy". In Craig JV (ed.).Estrogen Action, Selective Estrogen Receptor Modulators And Women's Health: Progress And Promise. World Scientific. pp. 229–254.doi:10.1142/9781848169586_0010.ISBN 978-1-84816-959-3.
ERTooltip Estrogen receptor
Agonists
Mixed
(SERMsTooltip Selective estrogen receptor modulators)
Antagonists
GPERTooltip G protein-coupled estrogen receptor
Agonists
Antagonists
Unknown
Retrieved from "https://en.wikipedia.org/w/index.php?title=Nafoxidine&oldid=1292605257"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp